Holmes Biopharma, Inc.

Holmes Biopharma, Inc.

December 19, 2006 10:49 ET

Holmes Biopharma-Contracts and Revenue Continue to Grow

SCOTTSDALE, ARIZONA--(CCNMatthews - Dec. 19, 2006) - Holmes Biopharma, Inc. (PINK SHEETS:HLMB) announces that sales efforts for its Phase 1 clinic in Omaha, Nebraska continue to show strong growth. The company had revenue of approximately $200,000 in December 2006, and plans to reach the $2 million mark on signed contracts by February 2007.

"We have completed the first few projects and our clients are very pleased with the level of service they received. We expect to see follow-up projects from all these clients in first quarter of 2007," stated Sohail Khattak, President and CEO of Qualia.

The Company expects solid first and second quarter bookings as clients are planning their projects for next year.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information